

Time and date: 10 a.m.–3 p.m.,
September 16, 1998.

Location: NIOSH, CDC, Room 1046,
1095 Willowdale Road, Morgantown,
West Virginia 26505.

Status: Open to the public, limited
only by the space available. The meeting
room accommodates approximately 50
people.

Purpose: Participants will provide
NIOSH with their individual advice and
comments regarding the technical and
scientific aspects of the study protocol,
Assessment of Workers' Postural
Stability and Cardiovascular Reactivity
While Working in a Restricted and
Elevated Space, being conducted at
NIOSH. Participants on the peer review
panel will review the study protocol
and provide individual advice on the
conduct of the study. Viewpoints and
suggestions from industry, labor,
academia, other governmental agencies,
and the public are invited.

**CONTACT PERSON FOR ADDITIONAL
INFORMATION:** Brian Dotson, M.S.,
NIOSH, CDC, M/S P119, 1095
Willowdale Road, Morgantown, West
Virginia 26505, telephone 304/285–
6142.

Dated: July 28, 1998.

Carolyn J. Russell,

*Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention (CDC).*

[FR Doc. 98–20857 Filed 8–4–98; 8:45 am]

BILLING CODE 4160–19–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 98F–0635]

General Electric Co.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration,
HHS.

ACTION: Notice.

SUMMARY: The Food and Drug
Administration (FDA) is announcing
that General Electric Co. has filed a
petition proposing that the food additive
regulations be amended to provide for
the expanded safe use of phosphorous
acid, cyclic butylethyl propanediol,
2,4,6 tri-*tert*-butylphenyl ester, which
may contain up to 1 percent by weight
of triisopropanolamine, as an
antioxidant and/or stabilizer for
polypropylene intended for use in
contact with food.

FOR FURTHER INFORMATION CONTACT: Vir
D. Anand, Center for Food Safety and
Applied Nutrition (HFS–216), Food and

Drug Administration, 200 C St. SW.,
Washington, DC 20204, 202–418–3081.

SUPPLEMENTARY INFORMATION: Under the
Federal Food, Drug, and Cosmetic Act
(sec. 409(b)(5) (21 U.S.C. 348(b)(5))),
notice is given that a food additive
petition (FAP 8B4615) has been filed by
General Electric Co., One Lexan Lane,
Mt. Vernon, IN 47620–9364. The
petition proposes to amend the food
additive regulations in § 178.2010
*Antioxidants and/or stabilizers for
polymers* (21 CFR 178.2010) to provide
for the expanded safe use of
phosphorous acid, cyclic butylethyl
propanediol, 2,4,6-tri-*tert*-butylphenyl
ester, which may contain up to 1
percent by weight of
triisopropanolamine, as an antioxidant
and/or stabilizer for polypropylene
complying with § 177.1520(c), items 1.1,
1.2, or 1.3, intended for use in contact
with food.

The agency has determined under 21
CFR 25.32(i) that this action is of the
type that does not individually or
cumulatively have a significant effect on
the human environment. Therefore,
neither an environmental assessment
nor an environmental impact statement
is required.

Dated: July 24, 1998.

Laura M. Tarantino,

*Acting Director, Office of Premarket
Approval, Center for Food Safety and Applied
Nutrition.*

[FR Doc. 98–20824 Filed 8–4–98; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Clinical Studies of Safety and Effectiveness of Orphan Products; Availability of Grants; Request for Applications

AGENCY: Food and Drug Administration,
HHS.

ACTION: Notice.

SUMMARY: The Food and Drug
Administration (FDA) is announcing
changes to its Orphan Products
Development (OPD) grant program for
fiscal year (FY) 1999. The previous
announcement of this program, which
was published in the **Federal Register** of
July 9, 1997, is superseded by this
announcement. In the future, a new
announcement will be published
annually.

DATES: The application receipt date is
November 2, 1998.

ADDRESSES: Application forms are
available from, and completed

applications should be submitted to:
Robert L. Robins, Grants Management
Officer, Division of Contracts and
Procurement Management (HFA–522),
Food and Drug Administration, 5600
Fishers Lane, rm. 2129, Rockville, MD
20857, 301–827–7185. (Applications
hand-carried or commercially delivered
should be addressed to 5630 Fishers
Lane, rm. 2129, Rockville, MD 20852.)

FOR FURTHER INFORMATION CONTACT:

Regarding the administrative and
financial management aspects of
this notice: Robert L. Robins
(address above).

Regarding the programmatic aspects
of this notice: Ronda A. Balham,
Office of Orphan Products
Development (HF–35), Food and
Drug Administration, 5600 Fishers
Lane, rm. 8–73, Rockville, MD
20857, 301–827–3668.

SUPPLEMENTARY INFORMATION: FDA is
announcing the anticipated availability
of funds for FY 1999 for awarding grants
to support clinical trials on the safety
and effectiveness of products for a rare
disease or condition (i.e., one with a
prevalence, not incidence, of fewer than
200,000 people in the United States).
Contingent on availability of FY 1999
funds, it is anticipated that \$11.3
million will be available, of which 8.8
million will be for noncompeting
continuation awards. This will leave
\$2.5 million for funding approximately
10 new applications. Any phase clinical
trial is eligible for up to \$100,000 in
direct costs per annum plus applicable
indirect costs for up to 3 years. Phase 2
and phase 3 clinical trials are eligible
for up to \$200,000 in direct costs per
annum plus applicable indirect costs for
up to 3 years.

FDA will support the clinical studies
covered by this notice under section 301
of the Public Health Service Act (the
PHS Act) (42 U.S.C. 241). FDA's
research program is described in the
Catalog of Federal Domestic Assistance,
No. 93.103.

The Public Health Service (PHS)
strongly encourages all grant recipients
to provide a smoke-free work place and
to discourage the use of all tobacco
products. This is consistent with the
PHS mission to protect and advance the
physical and mental health of the
American people.

PHS urges applicants to submit work
plans that address specific objectives of
"Healthy People 2000." Potential
applicants may obtain a copy of
"Healthy People 2000" (Full Report,
stock No. 017–001–00474–0) through
the Superintendent of Documents,
Government Printing Office,